JPMorgan Still Sees Moderna Overvalued Despite Raising Its Target

JPMorgan raised its price target for Moderna (MRNA) from $77 to $102 but maintained an Underweight rating, citing overvaluation. The increase follows Moderna's updated guidance and new expense framework, with key events expected in late 2026 or early 2027. JPMorgan notes a disconnect between Moderna's market value and its pipeline potential.

Original reporting
Published Nov 17, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 5:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$MRNA
Neutral
medium confidence
Mentioned
$MRNA
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$MRNANeutralMed
01

Why it matters

For trading, the key tension is higher upside framing (PT raised) versus persistent valuation caution (Underweight), with the next major event pegged to interim Phase II results for intismeran in late 2026 or early 2027.

02

Market read

A large-cap biotech analyst note can move positioning quickly, but the maintained Underweight suggests valuation risk remains the dominant debate.

03

What to watch

The note highlights a 2027 expense framework and cash balance; traders may focus more on cost trajectory and liquidity than on the pipeline valuation math.

Relevance 7/10Novelty 6/10Timing: premarket today after JPMorgan’s target change

Background

The piece ties JPMorgan’s target increase to Moderna’s analyst day, updated 2026 guidance, and a new expense framework extending into 2027 and beyond.

Company-level read

Ticker impact

$MRNANeutralMedium confidence
Context

JPMorgan raised Moderna’s price target to $102 but kept an Underweight rating, citing valuation disconnect versus the intismeran pipeline.

Expected impact

Likely choppy trading, with support from the higher target offset by continued Underweight positioning and valuation skepticism.

Evidence & confidence

The article combines a bullish PT revision with a bearish rating and explicit valuation rationale tied to pipeline support and next clinical catalyst timing.

Market effects

Biotech sentiment may tilt modestly toward oncology-focused platforms as expense guidance and Phase III momentum get re-framed.

Primarily US biotech/healthcare sentiment via a large-cap name’s analyst note.

Limited, as the catalyst is company-specific clinical timing and US analyst positioning.

Counterpoint

The Underweight call may be overly valuation-centric if intismeran’s next Phase II interim readout de-risks the pipeline faster than JPMorgan assumes.

Key entities

  • Moderna

    NASDAQ-listed biotech whose valuation and oncology pipeline are central to JPMorgan’s revised target and maintained Underweight stance.

  • intismeran

    Moderna’s cancer treatment referenced as the next catalyst via interim Phase II results in adjuvant kidney cancer.

  • JPMorgan

    Brokerage that raised Moderna’s price target from $77 to $102 while keeping an Underweight rating.

Related articles

$MRNAMed

Why is Moderna stock sliding today?

Moderna (MRNA) shares fell 3.8% to $212.50 as investors reassess its valuation after its 2026 Analyst Day. The company projected higher cash costs and deferred 2027 revenue guidance, disappointing investors. A norovirus vaccine trial also failed to meet early success criteria. Insider stock sales and a weak market for growth equities added to the pressure, though Moderna will be added to the MSCI World Index on November 30.

$MRNAMed

Moderna Sinks 12% in a Week. Bancel Wants an FDA Filing “Before the End of the Year”

Moderna (MRNA) fell 12% in the week to Nov. 13 after projecting $4B+ annual costs through 2030, primarily for cancer drug development, including intismeran with Merck (MRK). CEO Bancel aims for FDA filing by year-end. Analysts' 2028 revenue estimates are below annual costs, and the stock trades at a high sales multiple. BioNTech (BNTX), a rival, expects revenue to fall 35.4% this year.

$MRKMedAI 9/10

He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment

Merck (MRK) and Moderna (MRNA) reported a Phase 3 trial where a personalized vaccine, combined with Keytruda, kept 82.2% of melanoma patients cancer-free for two years, compared to 70.0% with Keytruda alone. The vaccine is not yet FDA-approved, so Medicare does not cover it outside of clinical trials. Patients may face out-of-pocket costs for trial participation.